Abstract:Background Pregnancy leads to physiological changes within the cardiovascular system such as increased plasma volume and cardiac output or hypercoagulability. These changes can be challenging for women with pre-existing cardiovascular disease with higher risks of complications. The guidelines of the European Society of Cardiology recommend treating high-risk patients in specialized centres by an interdisciplinary pregnancy heart team. In a team-based approach, the Pregnancy Heart Team was founded at our university hospital, in order to establish specific structures of communication and responsibility. Methods A prospective registry of all patients treated by the Pregnancy Heart Team between November 2022 and March 2024 was established. Patients consisted of women with pre-existing cardiovascular disease undergoing pregnancy as well as women who developed pregnancy-associated cardiovascular disease. Patients were evaluated throughout pregnancy by lab work and echocardiography during each trimester as well as in the postpartum period. Results In total 39 women (mean age 34±5 years) were prospectively included in the registry. 17 patients (43.5%) were classified as mWHO ≥ III. 17 patients (43.5 %) with pre-existing (pregnancy-associated) cardiovascular disease were managed throughout pregnancy and delivery. 9 patients (18.4 %) developed pregnancy-associated cardiovascular diseases such as peripartum cardiomyopathy or spontaneous coronary artery dissection. Preliminary data shows that mean left-ventricular ejection fraction remained stable during pregnancy with a non-significant trend towards lower values postpartum. Cardiac biomarkers such as high-sensitivity troponin T and NT-pro-BNP showed a non-significant trend towards increased values in the third trimester and postpartum. Adverse maternal outcomes occurred in 14 patients (35.9 %), including preterm premature rupture of membranes (12.2%), gestational hypertension (7.6%), gestational diabetes (5.1%), preeclampsia/eclampsia (7.6%) and delivery-associated complications (10.2%). Fetal complications included macrosomia (10.2%) or intrauterine growth retardation (5.1%). Discussion These preliminary data of a real-world patient collectivedemonstrate that a significant number of patients experienced adverse pregnancy outcomes which was associated with a trend towards increased cardiac biomarkers throughout pregnancy and postpartum. As recent studies have shown, interpretation of standard parameters such as cardiac biomarkers is not fully understood during pregnancy, especially in women with pre-existing cardiovascular disease. Our data may aid to understand prognostic implications of cardiac biomarkers during pregnancy.

OC17.01: Effect of antihypertensive therapy on pre‐ and postnatal cardiovascular parameters in hypertensive disorders of pregnancy: a human and animal model

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

OC17.06: *First trimester cardiac function in women with and without high risk of pre‐eclampsia

OP04.05: Effects of maternal Mediterranean diet on fetal cardiac function in high‐risk pregnancies: the IMPACT BCN trial

OC02.08: *Effect of Mediterranean diet or stress reduction interventions during pregnancy on placental volume and perfusion: IMPACT BCN trial sub‐analysis

EP17.24: Maternal ophthalmic artery Doppler in normal pregnancy and pre‐eclampsia and its association with pregnancy outcome

OC01.02: *Effect of aspirin on placental biomarkers profile in high‐risk women for pre‐eclampsia

P182 AORTIC VASCULAR BIOMARKERS FOR THE EARLY DETECTION OF PLACENTAL SYNDROMES DURING PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS

O22 MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022

EP01.61: Impact of physical models of fetal heart on prenatal care

The Immediate and Long-Term Impact of Preeclampsia on Offspring Vascular and Cardiac Physiology in the Preterm Infant

Multi-Organ Phenotypes of Offspring Born Following Hypertensive Disorders of Pregnancy: A Systematic Review

EP17.27: Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of adverse maternal outcomes in women with pre‐eclampsia

Preliminary data on short-term outcomes within the cardio-obstetrics registry

OP13.01: *Effective aspirin treatment for women at risk of pre‐eclampsia delays the metabolic clock of gestation

OC01.03: Uterine artery vasodilation and its impact on maternal and perinatal outcomes in aspirin‐using pregnant women for preterm pre‐eclampsia prevention

Modelling pre-eclampsia and its cardiovascular effects

EP11.07: The effect of maternal inflammatory rheumatic disease on the vasculature of offspring demonstrated on the umbilical cord

OP15.03: Maternal cardiovascular hemodynamics for the prediction of pre‐eclampsia at 12–16 weeks

Effects of antenatal corticosteroids on fetal hemodynamics: a longitudinal study